N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.

Galectin-3 (Gal-3) is secreted by activated macrophages. In hypertension, Gal-3 is a marker for hypertrophic hearts prone to develop heart failure. Gal-3 infused in pericardial sac leads to cardiac inflammation, remodeling, and dysfunction. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), a naturally occurring tetrapeptide, prevents and reverses inflammation and collagen deposition in the heart in hypertension and heart failure postmyocardial infarction. In the present study, we hypothesize that Ac-SDKP prevents Gal-3-induced cardiac inflammation, remodeling, and dysfunction, and these effects are mediated by the transforming growth factor (TGF)-beta/Smad3 signaling pathway. Adult male rats were divided into four groups and received the following intrapericardial infusion for 4 wk: 1) vehicle (saline, n = 8); 2) Ac-SDKP (800 microg x kg(-1) x day(-1), n = 8); 3) Gal-3 (12 microg/day, n = 7); and 4) Ac-SDKP + Gal-3 (n = 7). Left ventricular ejection fraction, cardiac output, and transmitral velocity were measured by echocardiography; inflammatory cell infiltration, cardiomyocyte hypertrophy, and collagen deposition in the heart by histological and immunohistochemical staining; and TGF-beta expression and Smad3 phosphorylation by Western blot. We found that, in the left ventricle, Gal-3 1) enhanced macrophage and mast cell infiltration, increased cardiac interstitial and perivascular fibrosis, and causes cardiac hypertrophy; 2) increased TGF-beta expression and Smad3 phosphorylation; and 3) decreased negative change in pressure over time response to isoproterenol challenge, ratio of early left ventricular filling phase to atrial contraction phase, and left ventricular ejection fraction. Ac-SDKP partially or completely prevented these effects. We conclude that Ac-SDKP prevents Gal-3-induced cardiac inflammation, fibrosis, hypertrophy, and dysfunction, possibly via inhibition of the TGF-beta/Smad3 signaling pathway.

[1]  R. V. van Leeuwen,et al.  N-Acetyl-Ser-Asp-Lys-Pro Inhibits Phosphorylation of Smad2 in Cardiac Fibroblasts , 2002, Hypertension.

[2]  N. Frangogiannis,et al.  The role of TGF-β Signaling in Myocardial Infarction and Cardiac Remodeling , 2007 .

[3]  M. Harmsen,et al.  Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice. , 2007, The American journal of pathology.

[4]  E. Heerkens,et al.  Integrins, vascular remodeling, and hypertension. , 2007, Hypertension.

[5]  J. Maessen,et al.  A systematic review of large scale and heterogeneous gene array data in heart failure. , 2005, Journal of molecular and cellular cardiology.

[6]  H. Schunkert,et al.  Increased Myocardial Collagen Content in Transgenic Rats Overexpressing Cardiac Angiotensin-Converting Enzyme Is Related to Enhanced Breakdown of N-Acetyl-Ser-Asp-Lys-Pro and Increased Phosphorylation of Smad2/3 , 2004, Circulation.

[7]  M. Chiariello,et al.  A biochemical method for the quantitation of myocardial scarring after experimental coronary artery occlusion. , 1986, Journal of molecular and cellular cardiology.

[8]  O. Jolobe.  Angiotensin-converting enzyme inhibitors. , 1995, British journal of hospital medicine.

[9]  Yigal M. Pinto,et al.  Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.

[10]  H. van Essen,et al.  Pharmacokinetic advantage of intrapericardially applied substances in the rat. , 2002, The Journal of pharmacology and experimental therapeutics.

[11]  R. Körfer,et al.  Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices. , 2008, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[12]  J. Michel,et al.  Doppler echocardiographic estimation of left ventricular end-diastolic pressure after MI in rats. , 2002, American journal of physiology. Heart and circulatory physiology.

[13]  P. Oettgen,et al.  Ets-1 is a critical regulator of Ang II-mediated vascular inflammation and remodeling. , 2005, The Journal of clinical investigation.

[14]  J. Damoiseaux,et al.  Rat macrophage lysosomal membrane antigen recognized by monoclonal antibody ED1. , 1994, Immunology.

[15]  H. Gabius,et al.  A Guide to Signaling Pathways Connecting Protein-Glycan Interaction with the Emerging Versatile Effector Functionality of Mammalian Lectins , 2006 .

[16]  Alberto Smith,et al.  Galectin-3 Is an Amplifier of Inflammation in Atherosclerotic Plaque Progression Through Macrophage Activation And Monocyte Chemoattraction , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[17]  R. Tarazi,et al.  Impaired Cardiac Contractile Response to Isoproterenol in the Spontaneously Hypertensive Rat , 1981, Hypertension.

[18]  K. Kayser,et al.  Determination of modulation of ligand properties of synthetic complex-type biantennary N-glycans by introduction of bisecting GlcNAc in silico, in vitro and in vivo. , 2004, European journal of biochemistry.

[19]  E. Ezan,et al.  Long-Term Effect of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline on Left Ventricular Collagen Deposition in Rats With 2-Kidney, 1-Clip Hypertension , 2001, Circulation.

[20]  N. Frangogiannis,et al.  The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. , 2007, Cardiovascular research.

[21]  Douglas L Mann,et al.  Inflammatory mediators and the failing heart: past, present, and the foreseeable future. , 2002, Circulation research.

[22]  J. Rysä,et al.  A role for cardiac mast cells in the pathogenesis of hypertensive heart disease , 2003, Journal of hypertension.

[23]  R. Kiss,et al.  Towards functional glycomics by localization of binding sites for tissue lectins: lectin histochemical reactivity for galectins during diethylstilbestrol-induced kidney tumorigenesis in male Syrian hamster , 2006, Histochemistry and Cell Biology.

[24]  M. Cavasin,et al.  Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension , 2004, Journal of hypertension.

[25]  D. Vaughan,et al.  Angiotensin-converting enzyme inhibitors. , 1998, Circulation.

[26]  H. Gabius,et al.  Galectin-3 Precipitates as a Pentamer with Synthetic Multivalent Carbohydrates and Forms Heterogeneous Cross-linked Complexes* , 2004, Journal of Biological Chemistry.

[27]  A. Kapke,et al.  Antifibrotic Effects of N -Acetyl-Seryl-Aspartyl-Lysyl-Proline on the Heart and Kidney in Aldosterone-Salt Hypertensive Rats , 2001, Hypertension.

[28]  H. Zimmer.  Measurement of left ventricular hemodynamic parameters in closed-chest rats under control and various pathophysiologic conditions , 2005, Basic Research in Cardiology.

[29]  O. Carretero,et al.  Novel anti-inflammatory mechanisms of N-Acetyl-Ser-Asp-Lys-Pro in hypertension-induced target organ damage. , 2008, American journal of physiology. Heart and circulatory physiology.

[30]  D. Potenza,et al.  Targeting integrins: insights into structure and activity of cyclic RGD pentapeptide mimics containing azabicycloalkane amino acids. , 2006, Bioorganic & medicinal chemistry.

[31]  S. Forbes,et al.  Regulation of Alternative Macrophage Activation by Galectin-31 , 2008, The Journal of Immunology.

[32]  M. Cavasin,et al.  Decreased Endogenous Levels of Ac-SDKP Promote Organ Fibrosis , 2007, Hypertension.

[33]  A. Hjerpe,et al.  Glycosaminoglycans in rat mucosal mast cells. , 1985, The Biochemical journal.

[34]  E. Papadimitriou,et al.  The tetrapeptide AcSDKP, an inhibitor of primitive hematopoietic cell proliferation, induces angiogenesis in vitro and in vivo. , 2003, Blood.

[35]  A. Singh,et al.  Resident cardiac mast cells: are they the major culprit in the pathogenesis of cardiac hypertrophy? , 2007, Basic & clinical pharmacology & toxicology.

[36]  O. Carretero,et al.  Ac-SDKP Reverses Cardiac Fibrosis in Rats With Renovascular Hypertension , 2003, Hypertension.

[37]  A. Motivala,et al.  Angiotensin-Converting Enzyme Inhibitors: A New Mechanism of Action , 2005, Circulation.

[38]  P. Ellinor,et al.  Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. , 2006, Journal of the American College of Cardiology.

[39]  O. Carretero,et al.  N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo. , 2004, American journal of physiology. Heart and circulatory physiology.

[40]  M. Entman,et al.  The inflammatory response in myocardial infarction. , 2002, Cardiovascular research.

[41]  Y. Benjamini,et al.  More powerful procedures for multiple significance testing. , 1990, Statistics in medicine.

[42]  J. Ménard,et al.  Acute angiotensin-converting enzyme inhibition increases the plasma level of the natural stem cell regulator N-acetyl-seryl-aspartyl-lysyl-proline. , 1996, The Journal of clinical investigation.

[43]  S. I. Rosenthal,et al.  SIRIUS RED F3BA AS A STAIN FOR CONNECTIVE TISSUE. , 1964, Archives of pathology.

[44]  O. Carretero,et al.  Effect of N-Acetyl-Seryl-Aspartyl-Lysyl-Proline on DNA and Collagen Synthesis in Rat Cardiac Fibroblasts , 2001, Hypertension.

[45]  O. Carretero,et al.  Ac-SDKP Reverses Inflammation and Fibrosis in Rats With Heart Failure After Myocardial Infarction , 2004, Hypertension.

[46]  O. Carretero,et al.  Reduction of Cardiac Fibrosis Decreases Systolic Performance Without Affecting Diastolic Function in Hypertensive Rats , 2004, Hypertension.

[47]  Hans-Joachim Gabius,et al.  Cell surface glycans: the why and how of their functionality as biochemical signals in lectin-mediated information transfer. , 2006, Critical reviews in immunology.